Collectively, our results clearly show that ER dilation via Ca2+ influx and ROS generation as well as c–FLIPL downregulation are critically involved in the potent anticancer effects of CDDO-Me on malignant breast cancer cells (Figure 9G). The gene discussed is CFLAR; the disease is breast cancer.